| Emily Moore, | |
|
3004 Pine St, Arkadelphia, AR 71923-5325 | |
| (870) 246-2471 | |
| (870) 246-2476 |
| Full Name | Emily Moore |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 3004 Pine St, Arkadelphia, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1730579921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R081681 (Arkansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Medical Center-arkadelphia | Arkadelphia, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baptist Health | 0648177949 | 71 |
News Archive
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.
› Verified 9 days ago
| Entity Name | Arkansas Health Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356481410 PECOS PAC ID: 7911802079 Enrollment ID: O20070607000040 |
News Archive
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.
› Verified 9 days ago
| Entity Name | Arkansas Health Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447568373 PECOS PAC ID: 7911802079 Enrollment ID: O20101116000177 |
News Archive
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.
› Verified 9 days ago
| Entity Name | Baptist Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841598919 PECOS PAC ID: 0648177949 Enrollment ID: O20110617000161 |
News Archive
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.
› Verified 9 days ago
| Entity Name | Baptist Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780094201 PECOS PAC ID: 0648177949 Enrollment ID: O20141030001538 |
News Archive
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.
› Verified 9 days ago
| Entity Name | Baptist Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528478955 PECOS PAC ID: 0648177949 Enrollment ID: O20141111002454 |
News Archive
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.
› Verified 9 days ago
| Entity Name | Baptist Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518356112 PECOS PAC ID: 0648177949 Enrollment ID: O20150413001105 |
News Archive
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.
› Verified 9 days ago
| Entity Name | Baptist Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427630110 PECOS PAC ID: 0648177949 Enrollment ID: O20210504000413 |
News Archive
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Moore, 3004 Pine St, Arkadelphia, AR 71923-5325 Ph: (870) 246-2471 | Emily Moore, 3004 Pine St, Arkadelphia, AR 71923-5325 Ph: (870) 246-2471 |
News Archive
Incoming House Ways and Means Subcommittee on Health Chair Pete Stark (D-Calif.) on Thursday said that the federal government has overpaid private Medicare Advantage plans by billions of dollars, the San Francisco Chronicle reports.
Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development
People at high risk of HIV infection can reduce their risk of acquiring the disease by taking antiretroviral drugs, according to Cochrane researchers. In an update of a systematic review first published in 2009, the researchers found that uninfected people in relationships with HIV-infected partners, men who have sex with men and those in other high risk groups are at a lower risk of becoming infected with the virus if they regularly take drugs that are normally prescribed to treat people with HIV.
Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the District of Delaware's March 31, 2012 decision that the asserted claims of U.S. Patent Nos. 7,410,978; 7,759,359; 7,781,448; 7,781,449 and 7,763,635 relating to Sanctura XR (trospium chloride extended-release capsules) are invalid.
› Verified 9 days ago
Mrs. Kristin Paige Brown, MSN, APRN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3004 Pine St, Arkadelphia, AR 71923 Phone: 870-245-2240 | |
Yuliya Riddle, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2914 Cypress Rd, Arkadelphia, AR 71923 Phone: 870-246-7000 | |
Alexandra Warner, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2850 Twin Rivers Dr, Arkadelphia, AR 71923 Phone: 870-246-8036 Fax: 870-246-7164 | |
Elva June Wolfe, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 303 Professional Park Dr, Arkadelphia, AR 71923 Phone: 870-464-1515 Fax: 870-464-1514 | |
Brittney Lee Shanek, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 303 Professional Park Dr, Arkadelphia, AR 71923 Phone: 870-464-1515 Fax: 870-464-1514 | |
Sharon Hayes, APN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2850 Twin Rivers Dr, Arkadelphia, AR 71923 Phone: 870-246-8036 | |
Tamara Tate, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2606 Pine St, Arkadelphia, AR 71923 Phone: 870-210-5243 |